Depression stigma, treatment-seeking intentions, and barriers to care among adolescents: demographic factors in a crowdsourced sample.

Psychiatry ResJun 1, 2026 (epub)
Clinical ResearchPsychiatry

Rotem Markman, Keren Steier, Chana T Fisch et al.

✦ AI-curated · Sources linked

In 30 seconds

This clinical trial investigated the impact of age, gender, and race/ethnicity on depression stigma, barriers to care, and treatment-seeking intentions among 1127 US adolescents aged 14-18. Results indicated that boys exhibited the highest stigma and lowest treatment-seeking intentions, while transgender and gender-diverse (TGD) youth faced the most barriers to care. Significant demographic differences were observed in these areas.

Key findings

  • Boys reported the highest depression stigma and lowest treatment-seeking intentions compared to girls and TGD youth.
  • TGD youth endorsed the highest barriers to care compared to boys.
  • Older adolescents showed higher treatment-seeking intentions and barriers to care than younger ones.
  • Significant differences in depression stigma were found across racial/ethnic groups.

Why it matters

Understanding the demographic factors influencing stigma and treatment-seeking can help clinicians develop targeted interventions to improve mental health care access for adolescents, particularly among vulnerable groups.

Source

PubMed · PMID 42250491

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.